Is this muscle pain caused by my statin?

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Shun Shin, Matthew J ^a   Francis, Darrel P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; MUSCLE DISEASE; MYALGIA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STUDY DESIGN; CHEMICALLY INDUCED; CROSSOVER PROCEDURE;

CROSS-OVER STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYALGIA; PRECISION MEDICINE;

EID: 85021272869     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j3030     Document Type: Editorial

References (9)

1. Krumholz HM. Statins evidence: when answers also raise questions. BMJ 2016;357:i4963. doi:10.1136/bmj.i4963. pmid:27628589.
2. Finegold JA, Shun-Shin MJ, Cole GD, et al. Distribution of lifespan gain from primary prevention intervention. Open Heart 2016;357:e000343. doi:10.1136/openhrt-2015-000343. pmid:27042321.
3. Fontana M, Asaria P, Moraldo M, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation 2014;357:2539-46. doi:10.1161/CIRCULATIONAHA.113. 007595. pmid:24744274.
4. Han BH, Sutin D, Williamson JD, et al. ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;357. doi:10.1001/jamainternmed.2017.1442. pmid:28531241.
5. Health and Social Care Information Centre. Prescriptions dispensed in the community, England: 2005 to 2015. 2016. https://www.gov.uk/government/statistics/prescriptionsdispensed-in-the-community-england-2005-to-2015
6. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;357:2532-61. doi:10.1016/S0140-6736(16)31357-5. pmid:27616593.
7. Fulcher J, O'Connell R, Voysey M, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;357:1397-405. doi:10.1016/S0140-6736(14)61368-4. pmid:25579834.
8. Gupta A, Thompson D, Whitehouse A, et al. ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;357:S0140-6736(17)31075-9. doi:10.1016/S0140-6736(17)31075-9. pmid:28476288.
9. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007;357:1761-70. doi:10.1016/j.clinthera.2007.08.022. pmid:17919557.